Cancer du sein : une spécialiste nous parle de cette épreuve - Dialogue avec le Dr Suzette Delaloge

Suzette de la Loge, a leading oncologist at Gustave Roussy, shares a profound vision for breast cancer care that balances scientific excellence with deep humanism. She argues that the initial shock of diagnosis is a pivotal moment that dictates much of the patient’s journey. A central, non-negotiable rule she proposes is that no patient should face a diagnosis alone. This is not merely for comfort; it is a strategic necessity to avoid what she calls the "double penalty." When a woman receives a diagnosis by herself, she is not only crushed by the weight of the news but is also forced to become the bearer of bad news for her family. This creates an immense burden of guilt and emotional labor. Having a companion allows for a shared absorption of the trauma and provides a "messenger" who can communicate with the outside world, relieving the patient of that immediate responsibility. At Gustave Roussy, de la Loge pioneered the "One-Day Diagnosis" model to address the agonizing wait times that often follow a suspicious screening. By condensing imaging, clinical exams, and biopsies into a single day, the medical team can provide immediate perspective and solutions. This approach acts as an "airbag" for the patient; while the diagnosis remains difficult, receiving it alongside a clear treatment plan makes it far more acceptable. Communication during this phase is critical, as many patients experience a "blackout" where they stop processing information the moment they hear the word "cancer." Doctors must therefore provide information in stages, ensuring the patient remains an active participant in their own care rather than a passive victim of an "avalanche" of data. Breast cancer is uniquely challenging because it strikes at the core of femininity, maternity, and bodily integrity. De la Loge notes that the disease is still not fully integrated into society’s understanding, unlike diabetes or other chronic illnesses. This leads to a lingering stigma and a profound sense of culpability. Patients often search for a rational cause—blaming a past divorce, stress, or lifestyle choices—or feel a deep sense of injustice if they have lived healthily. These psychological reactions, ranging from anger to denial, are natural but require careful management. The oncologist’s role is to help the patient navigate this internal upheaval while addressing the physical reality of the disease. The medical landscape has evolved significantly, moving toward highly personalized care. Breast cancer is categorized into three main types: hormone-dependent (the most common, treated with hormone therapy), HER2-positive (once the most aggressive, now highly treatable with targeted antibodies), and triple-negative (the most challenging, requiring intensive chemotherapy and immunotherapy). A major focus of modern oncology is "de-escalation"—the effort to avoid over-treating patients with toxic therapies if a lighter approach is statistically sufficient. This requires a shift from broad statistics to biological markers that identify who truly needs the heaviest treatments. Living with the disease involves more than just medical intervention; "support care" has become a pillar of recovery. This includes acupuncture for nausea, meditation, and psychological support. However, de la Loge identifies physical activity as the most critical non-medical intervention. It breaks the vicious cycle of fatigue: the more tired a patient feels, the less they move, which in turn increases exhaustion. Exercise, whether walking, yoga, or cycling, releases endorphins and improves treatment tolerance. The oncologist advocates for the "de-medicalization" of exercise, encouraging it as a social and natural activity rather than just a clinical prescription. While many localized cancers are curable, metastatic cancer remains a chronic challenge. It is "treatable but not curable," creating a "Groundhog Day" scenario where patients cycle through periods of remission and relapse as the cancer develops resistance. Emerging therapies, such as antibody-drug conjugates, offer hope by delivering high doses of chemotherapy directly to cancer cells, but they also bring renewed physical burdens. The goal in these cases is to maintain quality of life and control the disease for as long as possible, helping the patient maintain a sense of future even in the face of a non-curable condition. The transition from active treatment back to "normal" life is often the most neglected phase. Patients who were previously surrounded by medical staff suddenly feel abandoned by the healthcare system and misunderstood by a society that expects them to be "cured." Structured "after-cancer" programs, such as those offered by associations like "À chacun son Everest," are vital for addressing the long-term effects of treatment, including "brain fog" and physical scars. Reintegration into the workplace is another hurdle; de la Loge calls for greater benevolence from employers, advocating for flexible returns and a recognition that the patient is not the same person they were before. Finally, the role of the caregiver is highlighted as essential yet undervalued. Caregivers face their own exhaustion and need transparency from medical teams. They must be treated as part of a "triad" of care, ensuring they have the same information as the patient to avoid isolation. By changing how we view cancer—moving away from terror and toward a place of societal support—we can better welcome those who suffer and provide them with the dignity and care they deserve.